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Background 
Bisphosphonates are frequently used for 
prevention and treatment of osteoporosis.  They 
are also helpful in treating Paget’s disease of 
bone, hypercalcemia associated with malignancy, 
and osteolytic lesions associated with metastatic 
bone disease and multiple myeloma.  These bone 
resorption inhibitors increase bone density by 
binding to the bone matrix and slow down 
osteoclastic activity, thereby facilitating 
osteoblastic effectiveness.1-5  The bisphosphonate 
group of drugs include:  alendronate (Fosamax), 
etidronate (Didronel), ibandronate (Boniva), 
pamidronate (Aredia), risedronate (Actonel), 
tiludronate (Skelid), and zoledronic acid (Zometa) 
in the U.S.  In Canada alendronate (Fosamax), 
clodronate (Bonefos, Ostac), etidronate 
(Didronel), pamidronate (Aredia), risedronate 
(Actonel), and zoledronic acid (Zometa) are 
available.4 
Only Bonefos (or Ostac), Didronel, Aredia, 
and Zometa are currently available in intravenous 
dosage forms.4   
The most common side effect of the oral 
bisphosphonates is gastrointestinal upset.3  Post-
marketing adverse event reports for both oral and 
intravenous bisphosphonates have caused product 
information changes in their labeling.  Ocular side 
effects such as nonspecific conjunctivitis, scleritis, 
and uveitis have been reported.2  Recent reports 
from several countries have revealed severe bone, 
joint, and muscle pain associated with 
bisphosphonate use.5,6   
In 2003 and 2004, there were several reports of 
osteonecrosis of the jaw (ONJ) in cancer patients 
receiving chronic intravenous bisphosphonates.7-9  
The reports associated pamidronate (Aredia) and 
zoledronic acid (Zometa) with ONJ. Both 
products are produced by Novartis 
Pharmaceuticals Corporation and used for treating 
hypercalcemia of malignancy.  As a result, the 
products’ labeling was updated in the U.S. in 
August 2004 and in Canada in December 2004 to 
include precautions about ONJ.10-12 
 
Osteonecrosis of the Jaw 
Osteonecrosis, also called avascular necrosis 
of the bone or osteochondritis dissecans, is the 
death of bone resulting in the collapse of the 
bones’ structural architecture.  It leads to bone 
pain, loss of bone function, and bone destruction.  
It is the result of a number of conditions leading to 
an impairment of the blood supply to the bone.13 
Systemic corticosteroid therapy is a risk factor 
for osteonecrosis.  Osteonecrosis is a well 
documented complication of anti-cancer 
treatment.  Jaw bone is particularly vulnerable to 
osteonecrosis because of tooth and gum 
susceptibility to infection.  Special added risk 
factors for ONJ are trauma, as from dental 
procedures, and local anesthetics.14 
Bisphosphonates may present a unique role in 
the initiation of ONJ because of their novel 
antiangiogenic effects.  Wood et al identified that 
zoledronic acid has marked antiangiogenic 
properties which could enhance its efficacy in 
treatment of malignant bone disease.15  At the 
same time this property may increase the risk of 
ONJ.  In addition, because bisphosphonates are 
not metabolized, they remain in bone tissue for 
long periods of time.9  
Oral bisphosphonates have not been reported 
to have the same degree of association with ONJ 
as the intravenous products.  In a 2004 report from 
the FDA Adverse Event Reports database a total 
of 139 cases of osteonecrosis were identified from 
the marketing approval date of Aredia, Zometa, 
Fosamax, and Actonel until May 24, 2004.  
Thirty-four percent were associated with Aredia 
use, 24% per associated with Zometa, 42% per 
associated with patients who received both Aredia 
and Zometa, 8.6% were associated with Fosamax 
use, and one case was associated with Actonel.  
The majority of these patients were diagnosed 
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with osteonecrosis of the jaw.  Some had a 
diagnosis of mixed osteonecrosis and 
osteomyelitis.  Because of these findings, the 
report stated that osteonecrosis may be a class 
effect of the bisphosphonates.  The oral 
bisphosphonates are not as potent as the 
intravenous agents but they all have the same 
mechanism of action.16  Labeling for both 
Fosamax and Actonel is in the process of being 
updated to include this class osteonecrosis risk.  
Boniva labeling already has been updated.17 
 
Commentary 
The majority of cases with osteonecrotic jaw 
lesions occurred after a dental extraction yet some 
occurred spontaneously.7-9  Because of this 
association with dental procedures, potential 
preventative measures are suggested prior to 
bisphosphonate initiation. 
Preventative measures include: 
• Avoiding any elective jaw procedure  
• Baseline and routine dental exams including 
panoramic jaw radiography  
• Delaying bisphosphonate therapy, if risk 
factors allow, to complete dental procedures 
for teeth or dental structures with poor 
prognosis 
• Educating patients about the importance of 
good oral hygiene, symptom reporting, and 
regularly scheduled dental assessments18 
Patients already receiving bisphosphonates 
should: 
• Maintain excellent oral hygiene and have 
routine dental examinations 
• Obtain routine dental cleanings where careful 
attention is given to avoiding soft-tissue 
injury 
• Have aggressive nonsurgical management of 
any dental infection 
• Have root canal treatment if needed rather 
than dental extraction when possible18 
Patients with osteonecrosis or suspected 
osteonecrosis should receive immediate attention 
from an oral surgeon or dental oncologist.18  
Suspected problems associated with 
bisphosphonates should be reported.  To report 
adverse events in the US, call the FDA 
MEDWATCH program at 1-800-FDA-1088. The 
MEDWATCH program is also available on-line at 
www.fda.gov/medwatch.  In Canada, call the 
Canadian Adverse Drug Reaction Monitoring 
Program at 1-866-234-2345.  The Canadian 
adverse reaction reporting form can be found at: 
http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-
dpt/adverse_e.pdf.  It should be completed and 
faxed to 1-866-678-6789.   
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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